Camidanlumab Tesirine for the Treatment of R/R Hodgkin Lymphoma
Alex F. Herrera, MD, discusses the use of the antibody-drug conjugate, camidanlumab tesirine for the treatment of relapsed or refractory Hodgkin lymphoma.
Alex F. Herrera, MD, a hematologist/oncologist at the City of Hope Cancer Center, discusses the use of the antibody-drug conjugate, camidanlumab tesirine for the treatment of relapsed/ refractory (R/R) Hodgkin lymphoma (HL).
There are many treatment options available for patients living with R/R HL. Drugs like rituximab (Rituxan), nivolumab (Opdivo), and pembrolizumab (Keytruda) have greatly improved survival rates for patients. But, according to Herrera, very few options remain for patients whose tumors are resistant to these drugs.
For patients who cannot be cured through these conventional means, treatment options are desperately needed. Camidanlumab tesirine works by binding CD25 and delivers chemotherapy to the cancer cell.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma
September 11th 2024The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.
Read More
